Enlivex Therapeutics Ltd. (ENLV) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Ness Ziona, Israel. The current CEO is Oren Hershkovitz.
ENLV has IPO date of 2014-07-31, 71 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $19.47M.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
